Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIOT: BF Spiromax vs Symbicort Turbohaler in Asthma
NCT02062463Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2014
- Primary completion
- Mar 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of budesonide and formoterol in asthma (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Percentage of Participants Achieving Device Mastery at Day 1 and Percentage of Participants Maintaining Device Mastery at Week 12. Started May 2014; status: completed.
02
Drugs
budesonideformoterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02062463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02062463.